

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>Date Submitted: August 21, 2007</p> <p>(use as many sheets as necessary)</p>			
<p><i>Complete if Known</i></p>			
<p>Application Number</p>		10/567,328	
<p>Filing Date</p>		8/6/2004	
<p>First Named Inventor</p>		Makoto SAWADA	
<p>Art Unit</p>		Unassigned	
<p>Examiner Name</p>		Unassigned	
<p>Attorney Docket Number</p>		084335-0201	
Sheet	1	of	1

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	C1	WO 2004/015392 A2	2/19/2004	TARGETED MOLECULES CORP.		

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
	C2	IMAI et al., "Migration activity of microglia and macrophages into rat brain," Neuroscience Letters, 1997, 237:49-52.	
	C3	KANG et al., "Stability of the Disulfide Bond in an Avidin-Biotin Linked Chimeric Peptide During in vivo Transcytosis Through Brain Endothelial Cells", Journal of Drug Targeting, 2000, Vol. 8, No. 6, pp. 425-434.	
	C4	PASQUALINI et al., "Organ targeting in vivo using phage display in vivo using phage display peptide libraries", Nature, 1996, Vol. 380, No. 6572, pp. 364-366.	
	C5	SAWADA et al., "Brain-specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain", FEBS Letters, 1998, Vol. 433, pp. 37-40.	
	C6	SCHWARZE, et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse", Science, 1999, Vol. 285, No. 5433, pp. 1569-1572.	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.